Table 1.

Summay of clinical trials in HCC that were ongoing at the time of this writing (March 2, 2015) (ClinicalTrials.gov, 2013).

Agent	Molecular targets	Company/Sponsor	Phase
Sorafenib + BIIB022	N/A	Biogen	I
Cetuximab	EGFR inhibitor	Massachusetts General Hospital	II
Lenvatiniba	VEGFR, FGFR, PDGFR, RET, SCFR	Eisai Limited	III
Regorafeniba	VEGFR, FGFR, PDGFR, KIT, BRAF, RET	Bayer	III
Cabozantiniba	c‐MET, VEGFR, RET	Exelixis	III
Tremelimumab with Chemoembolization or Ablation	anti CTLA‐4	National Cancer Institute	I
Nivolumaba (BMS‐936559)	anti PD‐1	Bristol‐Myers Squibb	I
Fluorouracil implants (regional chemotherapy)	N/A	Simcere Pharmaceutical Group	II
AZD9150	ISIS‐STAT3	AstraZeneca	I
Axitiniba	VEGFR, PDGFR, c‐KIT	University Health Network, Toronto	II
SOM230	Somatostatin peptidomimetic	University of Miami	II
ADI‐PEG 20 vs placebo	N/A	Polaris Group	III
BYL719	PIK3CA	Novartis	I
AZD5363		AstraZeneca	I
BGJ398/BYL719		Novartis	I
MEK162 + BYL719		Novartis	I/II
MK2206	AKT	NCI	II
Vaccine therapy +/− sirolimus with NY‐ESO‐1	mTOR	Roswell Park Cancer Institute	I
Temsirolimus + sorafeniba		Philipps University Marburg Medical Center	I/II
CC‐223	Dual mTOR	Celgene	I/II
MSC2156119J	cMET	Germany	I
OMP‐54F28	WNT	Norris Comprehensive Cancer CenterUniversity of ColoradoIU Health University HospitalMassachusetts General HospitalMount Sinai Medical CenterFox Chase Cancer Center	I
TRC105	Endoglin	NIH	I/II

Indicates clinical trials which are being conducted internationally.